We previously found that FoxM1B is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly angiogenic glioblastoma in nude mice. However, the molecular mechanisms by which FoxM1B enhances glioma angiogenesis are currently unknown.
Introduction
Glioblastoma is the most common type of brain tumor and is associated with high morbidity and mortality rates. Patients with glioblastoma routinely undergo surgery followed by adjuvant radiation therapy and chemotherapy. Despite such aggressive treatment approaches, median survival times remain under 1 year in most cases. Brain tumor growth and progression depends on the establishment of an adequate blood supply (i.e., angiogenesis), which confers a tremendous survival and growth advantage on the malignant cells. Glioblastomas are among the most angiogenic of all human tumors, and the level of angiogenesis in glioblastomas is closely correlated with the degree of malignancy and patient prognosis (1) .
The glioblastoma angiogenic phenotype is characterized by an increase in the production of proangiogenic molecules by the tumor cells and organ-specific environments (2) . Previous studies have established that glioblastoma cells overexpress many growth factors, including vascular endothelial growth factor (VEGF), and several transcription activators have been identified in the VEGF promoter, including hypoxia-inducible factor 1 and signal transducer and activator of transcription 3 (Stat3). Hypoxia-inducible factor 1 mediates the hypoxia-induced transactivation of the VEGF promoter. However, an elevated level of VEGF production can often be detected in tumor cells located in the extreme periphery of the tumor where there is no apparent hypoxia. In addition, many glioblastoma cell lines express high levels of VEGF, even under normoxic conditions (3) , suggesting that glioblastomas can constitutively express VEGF without any apparent external stimuli. Moreover, Stat3 may not be an important transcription factor for VEGF in glioblastoma because Stat3 plays an opposing role in glial transformation depending on the genetic background of the tumor (4). For example, several studies found that Stat3 promoted the survival of some glioblastoma cell lines in vitro (5, 6) , whereas other studies found that Stat3 activity was absent in most glioblastomas (7, 8) . Given the prominent role of VEGF in glioma angiogenesis, it is critical to understand the molecular basis of constitutive VEGF gene expression.
FoxM1 is a member of the Forkhead box (Fox) transcription factor family, which is a master regulator of the cell cycle (9) (10) (11) (12) . Previous studies have found that FoxM1 is substantially elevated in several aggressive human carcinomas and can contribute to oncogenesis in many tissue types, including basal cell, breast, hepatocellular, prostate, lung, and colorectal cancers (13) (14) (15) (16) (17) . Increasing evidence indicates that FoxM1 may also contribute to oncogenesis in gliomas. For example, two studies found that aberrant FoxM1 expression was a common molecular alteration in malignant glioma (18, 19) . In our own studies of the functional significance of this factor, we found that FoxM1B was the predominant FoxM1 isoform in human gliomas but not in normal brain tissue (17) . We further found that the level of FoxM1 protein expressed in human glioma tissue correlated directly with glioma grade, and the FoxM1 protein level in human glioblastoma tissue correlated inversely with patient survival duration (17) . In animal models, increased levels of FoxM1B expression enhanced the tumorigenicity and invasiveness of glioma cells (17, 20) . In addition, increased FoxM1 expression in anaplastic astrocytoma cells led to the formation of highly angiogenic glioblastoma (17) . In fact, glioblastomas are defined, in part, by the appearance of proliferating endothelial cells and high blood vessel densities, which histologically distinguish grade 4 tumors from lower-grade astrocytomas (21) .
These findings underscore the importance of determining the molecular mechanisms by which FoxM1 regulates angiogenesis of glioma. Therefore, we sought to determine the effect of FoxM1 expression on VEGF expression and the angiogenesis of gliomas.
Materials and Methods
Primary human glioma specimens and immunohistochemical analysis. We stained tissue sections from paraffin-embedded glioma specimens with an antibody against human FoxM1 (MPP2 K-19; Santa Cruz Biotechnology) or an antihuman VEGF antibody (A-20; which slightly cross-reacts with mouse VEGF protein; Santa Cruz Biotechnology). We used tissue sections immunostained with nonspecific IgG as negative controls. We quantitatively scored the tissue sections according to the percentage of positive cells and staining intensity, as previously defined (22): We assigned a proportion score of 0 if 0% of the tumor cells showed positive staining; 1 if 0% to 1% of cells were stained; 2 if 1% to 10% stained; 3 if 11% to 30% stained; 4 if 31% to 70% stained; and 5 if 71% to 100% stained. We rated the intensity of staining on a scale of 0 to 3: 0, negative; 1, weak; 2, moderate; and 3, strong. We then combined the proportion and intensity scores to obtain a total score (range, 0-8) as described previously (22) . The use of human glioma specimens and database was approved by the institutional review board at The University of Texas M. D. Anderson Cancer Center.
Immunofluorescent staining of glioma specimens. Tissue sections of 5-Am thickness were cut from frozen glioblastoma specimens and processed for immunofluorescence. Sections were immunostained with rabbit anti-FOXM1 and mouse anti-VEGF antibodies (Santa Cruz Biotechnology) and then stained with 4 ¶,6-diamidino-2-phenylindole (DAPI), antirabbit IgG conjugated with Alexa 488, and anti-mouse IgG conjugated with Texas red (Molecular Probes). The fluorophore was excited by laser at 405, 488, or 543 nm and detected by a scanning confocal microscope (FV-1000, Olympus).
Cell lines and culture conditions. We purchased the SW1783 (human anaplastic astrocytoma) and U-87MG (glioblastoma) cell lines from American Type Culture Collection. We also used the HFU-251MG (glioblastoma) cell line, which we described previously (23) . All of the cell lines were maintained in plastic flasks as adherent monolayers in DMEM supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, L-glutamine, and a vitamin solution (Invitrogen).
Animals. We purchased female athymic BALB/c nude mice from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility. The mice were housed in laminar flow cabinets under specific pathogen-free conditions and used at 8 wk of age. The animals were maintained according to the Institutional Regulations in Facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care in accordance with current regulations and standards of the U.S. Department of Agriculture, Department of Health and Human Services, and NIH.
Northern blot analysis. Cellular mRNA was extracted from glioma cells using the FastTrack mRNA isolation kit (Invitrogen), fractionated on a 1% denaturing formaldehyde agarose gel, electrotransferred onto a nylon membrane, and cross-linked with UV light. We performed Northern hybridization using [ 32 P]dCTP-radiolabeled FoxM1 or VEGF cDNA probes. Equal mRNA loading was monitored by hybridizing the same membrane with a h-actin cDNA probe.
Real-time reverse transcription-PCR. We performed real-time reverse transcription-PCR (RT-PCR) analysis of the FoxM1 and VEGF genes, and we used glyceraldehyde-3-phosphate dehydrogenase as an internal control.
Total RNA was isolated with TRIzol reagent (Invitrogen). First-strand cDNA was synthesized from 2 Ag of total RNA by using Moloney murine leukemia virus reverse transcriptase (Invitrogen). We performed real-time PCR using 2 AL of cDNA and the SYBR Green Master Mix (Bio-Rad) as recommended by the manufacturer. The forward and reverse primers for FoxM1 and VEGF were as follows: FoxM1 primers, 5 ¶-TGCCCAGCAGTCTCTTACCT-3 ¶ (forward) and 5 ¶-CTACCCACCTTCTGGCAGTC-3 ¶ (reverse); VEGF 165 primers, 5 ¶-CAGATTATGCGGATCAAACCTCA-3 ¶ (forward) and 5 ¶-CAAGGCCCA-CAGGGATTTTC-3 ¶ (reverse). Each sample was run in triplicate for the target gene and the internal control gene.
Western blot analysis. Whole-cell lysates were prepared from glioma cells as described previously (17) . We performed standard Western blot analyses of the whole-cell lysates with an antibody against FoxM1 or anti-VEGF antibody (Santa Cruz Biotechnology) and a second anti-rabbit IgG antibody (Amersham Life Sciences). The membranes were then stripped and blotted with an anti-h-actin antibody (Sigma Chemical Co.) and used as loading controls. We detected the probe proteins using an enhanced chemiluminescence system (Amersham Life Sciences) according to the manufacturer's instructions.
Transit or stable transfection of glioma cells. To overexpress FoxM1, we transfected SW1783 and Hs683 cells with 3 mg of pcDNA3.1-FoxM1B or control vector pcDNA3.1 plasmids (17) . Stably transfected cell lines were isolated by selection with G418. To inhibit FoxM1 expression, we transfected U-87MG and HFU-251MG cells with a FoxM1 siRNA oligonucleotide (50 nmol/L) with the sequence CUCUUCUCCCUCAGAUAUAdTdT (17) or control siRNA (50 nmol/L). U-87MG and HFU-251MG cells were also transfected with the FoxM1-shRNA expression vector (17) or control vector for stable transfection. Stably transfected cell lines were isolated by G418 selection. To avoid clonal selection, we pooled all of the G418-resistant colonies to establish stable transfectants.
Promoter reporters and dual-luciferase assay. The full-length VEGF promoter was described previously (24) . We generated mutant VEGF promoters by site-specific mutagenesis, as described below. Glioma cells were transfected with the VEGF promoter reporter plasmids. Transfection efficiency was normalized by cotransfection with a h-actin-Renilla luciferase reporter containing a full-length Renilla luciferase gene (20) . We quantified both firefly and Renilla luciferase activity using a dual-luciferase assay system (Promega). We then calculated specific VEGF promoter activity as described previously (20) .
Electrophoretic mobility shift assay. We performed electrophoretic mobility shift assays (EMSA) as described previously (24) . We used double-stranded oligonucleotides of putative FoxM1-binding sites in the VEGF promoter as probes. For supershift analyses, the cell extracts were preincubated with specific antibodies against FoxM1 (Santa Cruz Biotechnology).
Chromatin immunoprecipitation assay. We performed chromatin immunoprecipitation assays using the chromatin immunoprecipitation assay kit from Upstate Biotechnology. Briefly, cultured cells were crosslinked with 1% formaldehyde and resuspended in 200 AL of SDS lysis buffer [1% SDS, 10 mmol/L EDTA, 50 mmol/L Tris-HCl (pH 8.1)] and sonicated on ice to shear the DNA to 200 to 500 bp. The chromatins were precleared by incubation with protein A-Sepharose beads for 2 h at 4jC. Anti-FoxM1 antibodies were then added, and the samples were incubated overnight at 4jC. We used immunoprecipitation with normal rabbit IgG as a negative control. Immunocomplexes were precipitated for 2 h with protein A-Sepharose beads, and DNA was recovered by means of phenolchloroform extraction. We then subjected the DNA to PCR to amplify a 215-bp region (À1,635 to À1,420 bp) of the VEGF promoter using the primers 5 ¶-GGAGCGTTTTGGTTAAATTGAG-3 ¶ and 5 ¶-TGCATATAGGAAG-CAGCTTGGA-3 ¶ or to amplify a 192-bp region (À634 to À442 bp) of the VEGF promoter using the primers 5 ¶-CCCCTTTCCAAAGCCCATTCC-3 ¶ and 5 ¶-CCTTCTCCCCGCTCCAACACCC-3 ¶. The PCR products were resolved electrophoretically on a 2% agarose gel and visualized by ethidium bromide staining.
Site-specific mutagenesis of the VEGF promoter. We performed site-specific mutagenesis of the VEGF promoter pGL3-V2274 using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. We confirmed the mutations by DNA sequencing.
Endothelial cell tube formation assay. We performed a tube formation assay as described previously (25) . Briefly, 250 AL of growthfactor-reduced Matrigel (Collaborative Biomedical Products) was pipetted into each well of a 24-well plate and polymerized for 30 min at 37jC. Human umbilical vein endothelial cells (HUVEC) were harvested after trypsin treatment and suspended in conditioned medium from 1 Â 10 6 glioma cells. Next, 2 Â 10 4 HUVECs in 300 AL of conditioned medium were added to each well and incubated at 37jC in 5% CO 2 for 20 h. We then photographed the cultures under a bright-field microscope. The quantified results were expressed in number of capillary tubes formed per square millimeter.
Intracranial human glioma xenograft model. Glioma cells (1 Â 10 6 ) were injected intracranially into nude mice as described previously (26) . We performed two independent experiments with five mice per group in each experiment. Animals showing general or local symptoms were euthanized; the remaining animals were euthanized 90 d after glioma cell injection. Each mouse's brain was harvested, fixed in 4% formaldehyde, and embedded in paraffin. We then determined the tumor formation and phenotype by histologic analysis of H&E-stained sections.
Immunohistochemical analysis of xenograft tumors. Brain tissue specimens were fixed by neutral buffered formalin, embedded in paraffin, and sectioned according to standard protocols. Tissue sections were immunostained with antibodies to FoxM1, VEGF (Santa Cruz Biotechnology), and von Willebrand factor ( factor VIII-related antigen; DAKO). For the quantification of the FoxM1 and VEGF expression, we measured the immunostaining score of FoxM1 or VEGF in 10 random 0.5-mm 2 fields at Â200 magnification of tumor tissues. The score is assigned according to the percentage of positive cells and staining intensity, as defined in the section of ''Primary human glioma specimens and immunohistochemical analysis.'' Two separate individuals who were both blinded to the slides examined and scored each sample. An average value of the two scores was presented in the present study. For quantification of tumor microvessel density, highly vascular areas were initially identified by scanning tumor sections using light microscopy at low power. Vessels in 10 high-power fields [Â200 magnification (20Â objective and 10Â ocular)] were counted by two independent investigators without knowledge of the patient outcome (double-blinded) as described previously (25) .
Statistical analysis. We determined the significance of differences in the patient specimen data using the m 2 test, the significance of differences in the in vitro data using the Student's t test (two-tailed), and the significance of differences in the in vivo data using the Mann-Whitney U test. P < 0.05 was considered to be significant.
Results
VEGF expression correlates with FoxM1 overexpression in human primary glioma specimens. We first determined the VEGF expression patterns in serial sections of 59 human glioblastoma (grade 4) specimens by immunohistochemical analyses. VEGF protein expression was present not only in tumor cells immediately surrounding necrotic areas (Fig. 1A, i) but also in the peripheral areas and in the central region of the glioma mass (Fig. 1A, i-iii) . In contrast, VEGF expression was absent from the ''normal'' brain tissues surrounding the glioma mass (Fig. 1A, i and ii) . Next, we examined FoxM1 expression in various areas of the glioma specimens. Similar to the pattern we observed for VEGF expression, we found FoxM1 protein expression in tumor cells surrounding necrotic areas, in the peripheral areas, and in the central regions of glioma tissues (Fig. 1A, iv-vi) . Colocalization of FoxM1 and VEGF expression was confirmed by double immunoflurorescent assay (Fig. 1B) . We then quantified the immunohistochemical staining of VEGF and FoxM1 in the glioma specimens on the 0 to 8 scale. We analyzed the scores and found a significant correlation between the FoxM1 and VEGF expression levels ( Fig. 1C, i ; r = 0.79, P < 0.001). We also determined the expression of VEGF and FoxM1 in 25 human anaplastic astrocytoma (anaplastic astrocytoma, grade 3) specimens and observed similar correlation between the expression of FoxM1 and VEGF in anaplastic astrocytoma tumors (Fig. 1C, ii ; r = 0.75, P < 0.001). Furthermore, we performed Western blot analyses using total protein extracts from three low-grade astrocytoma (grade 2), three anaplastic astrocytoma (grade 3), and six glioblastoma (grade 4) frozen human glioma tissues. As shown in Fig. 1D , VEGF expression correlated with FoxM1 expression. Therefore, our results suggest that VEGF expression in human glioma tissues can be detected in tumor cells located in the areas of the tumor where there is no apparent hypoxia as assessed by a lack of hypoxia marker carbonic anhydrase IX staining, and VEGF expression is correlated with FoxM1 expression (Supplementary Fig. S1A-D) .
Altered FoxM1 expression affects VEGF expression in glioma cells. To determine the effect of increased FoxM1 expression on VEGF expression, we studied two human glioma cell lines, SW1783 and Hs683, that had low levels of the FoxM1 protein (17) . We transfected these cells with the FoxM1B expression vector pcDNA3.1-FoxM1B or the control vector pcDNA3.1. To avoid clonal selection and variation, we pooled neomycin (G418)-resistant colonies to establish stable transfectants and designated them FoxM1B-transfected cell lines (SW1783-FoxM1 and Hs683-FoxM1). We found that forced expression of FoxM1B in SW1783 and Hs683 cells significantly increased FoxM1 mRNA and protein expression ( Fig. 2A, i and ii) . These cells also exhibited significantly increased VEGF mRNA and protein expression (Fig. 2A, i and ii) . Our results indicate that FoxM1 overexpression in glioma cells increased VEGF expression.
Conversely, to determine the effect of decreased FoxM1 expression on VEGF expression, we transfected FoxM1 siRNA (50 nmol/L) into HFU-251MG and U-87MG cells, which typically express high levels of FoxM1 (1). This transfection significantly inhibited FoxM1 mRNA and protein expression in both cell types (Fig. 2B, i and ii) ; the cell transfection also resulted in significantly decreased VEGF mRNA and protein expression in both cell types (Fig. 2B, i and ii) . These results indicate that blockade of FoxM1 expression suppressed VEGF expression in glioblastoma cells.
FoxM1 regulates VEGF promoter activity in glioma cells. To investigate the role of FoxM1 in regulating VEGF transcription, we studied whether FoxM1 regulates VEGF promoter activity. The VEGF promoter-luciferase construct pGL3-V2274 was cotransfected into SW1783 cells with pcDNA3.1-FoxM1B or the control vector pcDNA 3.1. Cotransfection with pcDNA3.1-FoxM1B activated the luciferase activity driven by the VEGF promoter in the SW1783 cell line (Fig. 3A, i) . Conversely, to assess the effect of decreased FoxM1 expression on VEGF transcription, we knocked down FoxM1 expression by cotransfecting FoxM1 siRNA and the VEGF promoter into U-87MG cells. FoxM1 siRNA inhibited the luciferase activity driven by the VEGF promoter in U-87MG cells (Fig. 3A, ii) . Our results suggest that FoxM1 was involved in VEGF promoter activity in glioma cells.
Direct interaction of FoxM1 with the VEGF promoter. To determine whether VEGF could be a direct transcriptional target of FoxM1, we analyzed the sequence of the VEGF promoter by using the FoxM1 consensus sequences 5 ¶-AGATTGAGTA-3 ¶ and 5 ¶-TAATCA-3 ¶ (27). We identified two putative FoxM1-binding regions in the VEGF promoter (Fig. 3B) . Using EMSA, we found that both binding regions specifically bound to nuclear protein prepared from HFU-251MG cells and resulted in the formation of one major shifted band (Fig. 3C) . Moreover, the shifted band could be supershifted by the FoxM1 antibody and competed out by an excess of the unlabeled FoxM1-binding region 1 or region 2 probe ( Fig. 3C; Supplementary Fig. S1E ), indicating that both binding regions were specifically bound to the FoxM1 protein.
Next, to provide direct proof that FoxM1 is recruited to the endogenous VEGF promoter during transcription in vivo, we performed standard chromatin immunoprecipitation assays with SW1783, SW1783-Neo, SW1783-FoxM1, and U-87MG cells. We found that both of the FoxM1-binding regions of the VEGF promoter bound to endogenous FoxM1 protein in all cell lines (Fig. 4A, i and ii) . Moreover, in the SW1783-FoxM1 and U-87MG cells that expressed high FoxM1 levels, five to six times more DNA promoter was bound to FoxM1 than in the SW1783 cells that expressed low FoxM1 levels (Fig. 4A, i and ii) . Collectively, our findings show that FoxM1 bound Frozen sections of glioblastomas were processed for triple immunofluorescence staining for FoxM1 (green ), VEGF (red), and nuclei (DAPI; blue ). These representative photos of three tumors indicate that many cells displayed strong positive nuclei staining but weak positive cytoplasm staining of FoxM1, whereas VEGF was predominantly in the cytoplasm of the cells. Merged photos indicated that FoxM1 and VEGF colocalized in the cells. C, we quantitatively scored the tissue sections according to the percentage of positive cells and staining intensity as described in Materials and Methods. We then combined the percentage and intensity scores to obtain a total score (range, 0-8). FoxM1 expression levels correlated positively with VEGF expression levels in glioblastoma samples (i, Pearson's correlation test r = 0.79; P < 0.001) and in anaplastic astrocytoma samples (ii, r = 0.75; P < 0.001). Note that some of the dots on the graphs represented more than one specimen (some scores overlapped). D, FoxM1 and VEGF protein expression levels from three low-grade astrocytoma (LGA), three anaplastic astrocytoma (AA), and six glioblastoma (GBM ) frozen tissues were determined by Western blot analysis.
specifically to FoxM1-binding sites in the VEGF promoter in vitro and in vivo.
FoxM1-binding sites are critical for the activation of the VEGF promoter in glioma cells. To assess the functional role of the FoxM1-binding sites in VEGF gene regulation, we performed site-specific mutagenesis within the FoxM1-binding sites of the VEGF promoter pGL3-V2274. As shown in Fig. 4B , various mutant reporters were generated from the wild-type VEGF promoter construct, including a FoxM1-binding site 1 mutation only (pGL3-V2274 Mut1), a FoxM1-binding site 2 mutation only (pGL3-V2274 Mut2), and both site 1 and site 2 mutations (pGL3-V2274 Mut1 and pGL3-V2274 Mut2). We transfected these mutant luciferase reporters into HFU-251MG cells and compared their activity with that of wild-type VEGF promoter pGL3-V2274 WT (Fig. 4C) . Disruption of one or both of the FoxM1-binding sites significantly attenuated VEGF promoter activity in HFU-251MG cells. In addition, disruption of one or both of the FoxM1-binding sites significantly inhibited VEGF promoter transactivation by pcDNA3-FoxM1 in SW1783 cells (Fig. 4C) . Our results suggest that the FoxM1-binding sites were critical for VEGF promoter activation in glioma cells.
Inhibition of FoxM1 expression suppresses the growth and angiogenesis of glioblastoma cells. Next, we examined the functional consequence of a FoxM1/VEGF interaction by assessing their roles in glioma growth. We established two stable FoxM1-shRNA-transfected U-87MG and HFU-215MG cell lines (U-87MG-FoxM1-shRNA-a and U-87MG-FoxM1-shRNA-b, and HFU-215MG-FoxM1-shRNA-a and HFU-215MG-FoxM1-shRNA-b) by performing duplicate transfection experiments with each cell line. Western blot analyses showed decreased levels of FoxM1 protein expression in the FoxM1-shRNA-transfected U-87MG and HFU-215MG cell lines (Fig. 5A ) . We then intracranially injected these cells into nude mice and found that U-87MG, HFU-215MG, and control-shRNA cells produced brain tumors in all of the injected mice ( Table 1 ). The mice became moribund f31 days after the injection. In contrast, except for a small tumor in one of the mice injected with U-87MG-FoxM1-shRNA-b cells, the FoxM1-shRNA-transfected U-87MG and HFU-215MG cells produced no brain tumors, which resulted in a significant increase in overall survival time (P < 0.001). Our results show that inhibition of FoxM1 expression by FoxM1 shRNA significantly suppresses the tumorigenicity of human glioblastoma cells.
Furthermore, we found that VEGF expression in FoxM1-shRNA-transfected U-87MG and HFU-215MG cells was decreased as compared with control-shRNA cells (Fig. 5A) . Thus, we next examined whether inhibition of FoxM1 expression in these tumor cells would affect brain tumor angiogenesis. We assessed glioma vascularization by staining mouse glioma tissue sections with an anti-von Willebrand factor antibody and found that gliomas produced by U-87MG control-shRNA cells were highly vascularized, whereas gliomas produced by U-87MG-FoxM1-shRNA-b cells had considerably lower microvessel density (Fig. 5B) . We evaluated VEGF expression in the brain tumors by means of immunohistochemical staining. Consistently, VEGF staining was prominent in the brain tumors formed by U-87MG control-shRNA cells, but not in the brain tumors formed by U-87MG-FoxM1-shRNA-b cells (Fig. 5B) .
To provide direct evidence that FoxM1 regulates the angiogenic phenotype of glioma cells, we determined the angiogenic ability of the FoxM1B-transfected and FoxM1-siRNA-transfected glioma cells using an endothelial cell tube formation assay. We found that the conditioned media from SW1783-FoxM1 cultures had greater angiogenic potential than the conditioned media from SW1783-Neo cultures (Fig. 5C ). In contrast, the conditioned media from U-87MG or HFU-251MG cells transfected with FoxM1 siRNA had a significantly reduced capillary tube formation compared with the conditioned media from cells transfected with control siRNA (Fig. 5C) . Collectively, our results indicate that FoxM1 regulates the angiogenic ability of glioma cells, at least in part, through regulation of VEGF expression.
Discussion
Our study sought to determine the molecular mechanism by which FoxM1 promotes glioma angiogenesis through the up-regulation of VEGF expression. We found that human glioma cells constitutively expressed VEGF and that the levels of constitutive FoxM1 expression strongly correlated with the levels of constitutive VEGF expression. Moreover, we found that FoxM1 transactivates VEGF through direct binding to the VEGF gene promoter. FoxM1 overexpression in glioma cells by transfection of a FoxM1B expression vector significantly up-regulated VEGF expression and the angiogenic ability of the glioma cells, whereas inhibition of FoxM1 by transfection of FoxM1 siRNA did the opposite. Therefore, FoxM1B overexpression contributes directly to VEGF overexpression in malignant gliomas and seems to be critical for glioma angiogenesis.
Several studies have indicated the importance of FoxM1 in the oncogenesis of several malignancies, including gliomas (13) (14) (15) (16) (17) . We previously found that FoxM1 protein expression levels in human glioblastoma tissues were inversely correlated with patient survival and that aberrant FoxM1 expression critically regulated the tumorigenicity of human glioma cells (17) . Our current study furthered our understanding of the mechanism of action of FoxM1 on glioma oncogenesis in several ways. First, our immunohistochemical analyses showed a significant correlation between FoxM1 overexpression and elevated VEGF expression in 59 glioblastoma specimens and provided evidence that FoxM1 regulates VEGF expression and glioma angiogenesis and growth. Our findings suggest that FoxM1 could be a critical pathway in glioma angiogenesis, which is supported by a recent report showing that FoxM1 siRNA reduced VEGF activity in pancreatic cancer cells (28) . Second, to our knowledge, this is the first report to show that VEGF is a direct target of FoxM1. Specifically, we identified two FoxM1-binding sites, mapped between À569 and À560 bp and between À1,528 and À1,523 bp of the proximal VEGF promoter. FoxM1 seemed to crucially regulate VEGF expression through direct interaction with the VEGF promoter, as mutation of the FoxM1-binding sites significantly down-regulated VEGF promoter activity in glioblastoma cells. Our findings using both FoxM1 overexpression and siRNA knockdown approaches further substantiated this finding. Finally, the levels of FoxM1 expression directly affected the angiogenic and tumorigenic ability of glioma cells in vitro and in orthotopic animal models. Thus, our study provides both clinical and mechanistic evidence that FoxM1 critically regulates VEGF expression and glioma angiogenesis and describes a novel molecular mechanism by which FoxM1 promotes glioma angiogenesis.
Many studies have also suggested that VEGF expression is regulated by a plethora of external factors in many types of normal and malignant cells (29) . Major stimulators of VEGF expression include hypoxia, which occurs frequently within diverse types of expanding tumors, particularly in regions surrounding necrotic areas (30) . The role of hypoxia in the angiogenesis switch has been clearly shown in a mouse model (31) . Hypoxia-mediated VEGF induction involves transactivation of a VEGF promoter by hypoxiainducible factor 1 (32, 33) , as well as stabilization of VEGF mRNA expression by proteins that bind to sequences located in the 3 ¶-untranslated region of VEGF mRNA (34) (35) (36) . Because human glioblastoma is generally hypoxic, the VEGF overexpression we observed in human glioblastoma tissues was due to hypoxia, at least in part (37, 38) . Conversely, in human glioblastomas, elevated VEGF production can often be detected in tumor cells located in the extreme periphery of the tumor where there is no apparent hypoxia. This observation is consistent with the results of previous studies (39) (40) (41) that found that exogenous factors, such as hormones, cytokines, and growth factors, modulate VEGF expression through different mechanisms than those operating in hypoxia-induced activation of the VEGF gene. For example, Maity and colleagues (39) found that activation of epidermal growth factor receptor (EGFR) on glioblastoma cells led to VEGF upregulation by a phosphatidylinositol 3-kinase/Akt-dependent pathway, which was distinct from the signals induced by hypoxia. In another study, fibroblast-derived growth factor and tumor necrosis factor-a enhanced VEGF transcription in human glioma cells through the transcription factor Sp1 (40) . In addition, interleukin-6 induced transcriptional activation of VEGF in glioblastoma cells by means of a direct interaction between Stat3 and Sp1 (41) . Nevertheless, previous studies on the regulation of VEGF expression have revealed the diverse complexity of VEGF transcriptional regulation (29, 42) . Thus, our current study adds a new mechanism to the body of research on the transcriptional regulation of VEGF expression by providing evidence that VEGF is a direct transcriptional target of FoxM1 and that FoxM1 critically controls constitutive VEGF expression in glioblastoma cells. Whether and how these pathways interact with and affect glioma angiogenesis warrants further investigations.
Recently, Kim and colleagues (43) reveal elegantly a lack of VEGF expression change in FoxM1-null embryo. This interesting finding indicates that in the development process, VEGF might be regulated by several redundant signaling pathways, whereas in tumor A, i and ii, chromatin immunoprecipitation assays were done with SW1783, SW1783-Neo, SW1783-FoxM1-a, and U-87MG cells. Chromatin fragments of the cells were immunoprecipitated with an anti-FoxM1 antibody (top ) or control IgG (middle ) and subjected to PCR. We subjected 1% of the total cell lysates to PCR before immunoprecipitation as inputs (bottom ). The relative band intensity was calculated as the ratio between precipitated and input DNA from each cell line. Columns, mean values obtained from three experiments; bars, SE. B, schematic structure of the VEGF promoter. The sequences of the FoxM1-binding sites are shown in both wild-type (WT ) and mutant (Mut) forms. C, VEGF promoter activity with and without mutations in the FoxM1-binding sites. HFU-251MG cells were transfected with the wild-type VEGF promoter or its mutants. Luciferase activity was then determined. In addition, SW1783 cells were cotransfected with the wild-type VEGF promoter or its mutants and pcDNA 3.1-FoxM1 (3 Ag), and luciferase activity was again determined. development and progression, tumor cell might predominantly depend on different signaling pathways to regulate VEGF expression. In our current report, we have provided both clinical and experimental evidence that FoxM1 plays an important regulatory role in VEGF expression and in angiogenesis of human glioma.
The mechanisms responsible for FoxM1 overexpression in malignant gliomas are still unknown; however, it is known that FoxM1 expression can be regulated by diverse stimuli including liver regeneration, keratinocyte growth factor, and oxidative stress (6) . The formation and malignant progression of gliomas are widely regarded as multistep processes resulting from complex interplay between multiple genetic and epigenetic events (44) (45) (46) (47) (48) (49) . Most human gliomas seem to have a set of pathways that are disrupted (e.g., pRB, p53, and PTEN; refs. [44] [45] [46] [47] [48] [49] as well as a set of pathways that are abnormally active (e.g., telomerase, EGFR, and Akt; refs. 44-49) in both processes. We are currently investigating whether these abnormal pathways lead to aberrant FoxM1B expression in malignant gliomas.
In summary, we found that FoxM1 directly regulated VEGF expression and glioblastoma angiogenesis and growth. Because of the diverse roles of FoxM1 in glioma progression, including regulation of tumor cell proliferation, tumor invasion, and angiogenesis, a better understanding of FoxM1 signaling and function may help identify novel and effective targets for malignant glioma treatment.
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